The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome

DSpace/Manakin Repository

The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome

Show simple item record

dc.contributor.author Melmed, Shlomo
dc.contributor.author Clemmons, David R.
dc.contributor.author Colao, Annamaria
dc.contributor.author Cunningham, Regina S.
dc.contributor.author Molitch, Mark E.
dc.contributor.author Vinik, Aaron I.
dc.contributor.author Adelman, Daphne T.
dc.contributor.author Liebert, Karen J. P.
dc.contributor.author Klibanski, Anne
dc.date.accessioned 2012-02-04T22:31:50Z
dc.date.issued 2009
dc.identifier.citation Klibanski, Anne, Shlomo Melmed, David R. Clemmons, Annamaria Colao, Regina S. Cunningham, Mark E. Molitch, Aaron I. Vinik, Daphne T. Adelman, and Karen J. P. Liebert. 2009. The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary 13(3): 266-286. en_US
dc.identifier.issn 1386-341X en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8123171
dc.description.abstract The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid syndrome, and the efficacy of extended dosing intervals were reviewed. Panel opinions, based on the level of available scientific evidence, were polled. Finally, their views were compared with those of surveyed community-based endocrinologists and neurosurgeons. en_US
dc.language.iso en_US en_US
dc.publisher Springer US en_US
dc.relation.isversionof doi:10.1007/s11102-009-0210-2 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913001/pdf/ en_US
dash.license LAA
dc.subject acromegaly en_US
dc.subject Carcinoid syndrome en_US
dc.subject neuroendocrine tumor en_US
dc.subject NET en_US
dc.subject somatostatin analogs en_US
dc.subject somatostatin analogues en_US
dc.subject lanreotide en_US
dc.subject octreotide en_US
dc.subject insulin-like growth factor-I en_US
dc.subject IGF-I en_US
dc.subject growth hormone en_US
dc.subject GH en_US
dc.title The Endocrine Tumor Summit 2008: Appraising Therapeutic Approaches for Acromegaly and Carcinoid Syndrome en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Pituitary en_US
dash.depositing.author Klibanski, Anne
dc.date.available 2012-02-04T22:31:50Z
dash.affiliation.other HMS^Medicine-Massachusetts General Hospital en_US

Files in this item

Files Size Format View
2913001.pdf 437.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters